These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 19383336

  • 1. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.
    Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, Smith-McCune K, Fishman D, Gray JW, Mills GB.
    Mol Oncol; 2008 Aug; 2(2):164-81. PubMed ID: 19383336
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells.
    Kodigepalli KM, Dutta PS, Bauckman KA, Nanjundan M.
    FEBS Lett; 2013 Jan 04; 587(1):5-16. PubMed ID: 23178716
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.
    Smith DM, Patel S, Raffoul F, Haller E, Mills GB, Nanjundan M.
    Cell Death Differ; 2010 Dec 04; 17(12):1867-81. PubMed ID: 20508647
    [Abstract] [Full Text] [Related]

  • 6. Transforming growth factor-β/SMAD Target gene SKIL is negatively regulated by the transcriptional cofactor complex SNON-SMAD4.
    Tecalco-Cruz AC, Sosa-Garrocho M, Vázquez-Victorio G, Ortiz-García L, Domínguez-Hüttinger E, Macías-Silva M.
    J Biol Chem; 2012 Aug 03; 287(32):26764-76. PubMed ID: 22674574
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Expression profiles of SnoN in normal and cancerous human tissues support its tumor suppressor role in human cancer.
    Jahchan NS, Ouyang G, Luo K.
    PLoS One; 2013 Aug 03; 8(2):e55794. PubMed ID: 23418461
    [Abstract] [Full Text] [Related]

  • 9. SnoN overexpression is predictive of poor survival in patients with esophageal squamous cell carcinoma.
    Akagi I, Miyashita M, Makino H, Nomura T, Hagiwara N, Takahashi K, Cho K, Mishima T, Takizawa T, Tajiri T.
    Ann Surg Oncol; 2008 Oct 03; 15(10):2965-75. PubMed ID: 18612694
    [Abstract] [Full Text] [Related]

  • 10. SnoN is a cell type-specific mediator of transforming growth factor-beta responses.
    Sarker KP, Wilson SM, Bonni S.
    J Biol Chem; 2005 Apr 01; 280(13):13037-46. PubMed ID: 15677458
    [Abstract] [Full Text] [Related]

  • 11. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
    Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, Mills GB.
    Cancer Res; 2007 Apr 01; 67(7):3074-84. PubMed ID: 17409414
    [Abstract] [Full Text] [Related]

  • 12. SnoN/SKIL modulates proliferation through control of hsa-miR-720 transcription in esophageal cancer cells.
    Shinozuka E, Miyashita M, Mizuguchi Y, Akagi I, Kikuchi K, Makino H, Matsutani T, Hagiwara N, Nomura T, Uchida E, Takizawa T.
    Biochem Biophys Res Commun; 2013 Jan 04; 430(1):101-6. PubMed ID: 23154181
    [Abstract] [Full Text] [Related]

  • 13. The downregulation of SnoN expression in human renal proximal tubule epithelial cells under high-glucose conditions is mediated by an increase in Smurf2 expression through TGF-β1 signaling.
    Li X, Diao Z, Ding J, Liu R, Wang L, Huang W, Liu W.
    Int J Mol Med; 2016 Feb 04; 37(2):415-22. PubMed ID: 26743567
    [Abstract] [Full Text] [Related]

  • 14. SnoN/SkiL, a TGFβ signaling mediator: a participant in autophagy induced by arsenic trioxide.
    Raffoul F, Campla C, Nanjundan M.
    Autophagy; 2010 Oct 04; 6(7):955-7. PubMed ID: 20699661
    [Abstract] [Full Text] [Related]

  • 15. Molecular basis for the cell type specific induction of SnoN expression by hepatocyte growth factor.
    Tan R, Zhang X, Yang J, Li Y, Liu Y.
    J Am Soc Nephrol; 2007 Aug 04; 18(8):2340-9. PubMed ID: 17625116
    [Abstract] [Full Text] [Related]

  • 16. SnoN: bridging neurobiology and cancer biology.
    Pot I, Ikeuchi Y, Bonni A, Bonni S.
    Curr Mol Med; 2010 Oct 04; 10(7):667-73. PubMed ID: 20712586
    [Abstract] [Full Text] [Related]

  • 17. Dual role of SnoN in mammalian tumorigenesis.
    Zhu Q, Krakowski AR, Dunham EE, Wang L, Bandyopadhyay A, Berdeaux R, Martin GS, Sun L, Luo K.
    Mol Cell Biol; 2007 Jan 04; 27(1):324-39. PubMed ID: 17074815
    [Abstract] [Full Text] [Related]

  • 18. The role of SnoN in transforming growth factor beta1-induced expression of metalloprotease-disintegrin ADAM12.
    Solomon E, Li H, Duhachek Muggy S, Syta E, Zolkiewska A.
    J Biol Chem; 2010 Jul 16; 285(29):21969-77. PubMed ID: 20457602
    [Abstract] [Full Text] [Related]

  • 19. The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins.
    He J, Tegen SB, Krawitz AR, Martin GS, Luo K.
    J Biol Chem; 2003 Aug 15; 278(33):30540-7. PubMed ID: 12764135
    [Abstract] [Full Text] [Related]

  • 20. Cytoplasmic SnoN in normal tissues and nonmalignant cells antagonizes TGF-beta signaling by sequestration of the Smad proteins.
    Krakowski AR, Laboureau J, Mauviel A, Bissell MJ, Luo K.
    Proc Natl Acad Sci U S A; 2005 Aug 30; 102(35):12437-42. PubMed ID: 16109768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.